293 cells were transfected with anti-GPC3-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Glypican 3, His Tag (Cat. No. GP3-HF2H1, 3 µg/ml) and C. FITC-labeled Protein Control. A. Non-transfected 293 cells and C. FITC-labeled Protein Control were used as negative control. RFP was used to evaluate CAR (anti-GPC3-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Glypican 3, His Tag (Cat. No. GP3-HF2H1) (QC tested).
Anti-human GPC3 MAb (chimeric mouse-human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Glypican 3, His Tag (Cat. No. GP3-H52H4) with an affinity constant of 1.33 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Anti-Human GPC3 MAb (chimeric mouse-human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Glypican 3 (S359F), His Tag, low endotoxin (Cat. No. GP3-H5223) with an affinity constant of 1.96 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Yongren Medical Innovation/Guangdong Zhaotai InVivo Biomedicine) | Phase 1 Clinical | Hunan Zhaotai Medical Group | Liver Neoplasms; Lung Neoplasms | Details | |
| GPC-3298306 | GPC-3298306 | Phase 2 Clinical | National Cancer Center Of Japan | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
| Anti-GPC3 CAR T-cell therapy (Nanjing University) | Phase 1 Clinical | Nanjing University | Carcinoma, Hepatocellular | Details | |
| GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details | |
| GLYCAR T cell therapy (Baylor College of Medicine) | GLYCAR | Phase 1 Clinical | Baylor College Of Medicine | Carcinoma, Hepatocellular | Details |
| MDX-1414 | MDX-1414 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| Anti-GPC3 chimeric antigen receptor T cell therapy (Shanghai Genechem) | Phase 2 Clinical | Shanghai Genechem Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular | Details | |
| Codrituzumab | GC-33; RG-7686; RO-5137382 | Phase 2 Clinical | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | Carcinoma, Hepatocellular | Details |
| B010-A | B010-A | Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Carcinoma, Hepatocellular | Details |
| GPC3-CAR-T cell therapy | CSG-GPC-3; KJgpc3-001; CAR-GPC3 T-cell; anti-GPC-3 CAR T; GPC3-CAR/CSG-GPC3 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
| Ori-CAR-001 | Ori-CAR-001 | Clinical | Carcinoma, Hepatocellular | Details | |
| ECT-204 | ECT-204; JWATM-204 | Phase 2 Clinical | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
This web search service is supported by Google Inc.
A-Z
